Pseudolaric acid B inhibits inducible cyclooxygenase-2 expression via downregulation of the NF-κB pathway in HT-29 cells

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 5, 2012, Pages 885-896

  Hou, Li ^a   Xu, Bo ^a   Guo, Wei ^a   Ran, Fu Xiang ^a   Liu, Jing Tao ^a   Yuan, Xia ^a   Fu, Hong Zheng ^a   Cui, Jing Rong ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Cyclooxygenase 2; Inflammation; Nuclear factor B; Pseudolaric acid B; Signal transducer and activator of transcription 3

Indexed keywords

CYCLOOXYGENASE 2; CYTOKINE; I KAPPA B; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROSTAGLANDIN E2; PSEUDOLARIC ACID B; STAT3 PROTEIN; SULFORHODAMINE B; CYCLOOXYGENASE 2 INHIBITOR; DITERPENE; HERBACEOUS AGENT; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; COLON CARCINOMA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HT 29 CELL LINE; METABOLISM; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DITERPENES; DOWN-REGULATION; DRUGS, CHINESE HERBAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HT29 CELLS; HUMANS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84863084635     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1120-z     Document Type: Article

References (41)

1. Alexander WS (2002) Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2:410-416 (Pubitemid 37328748)
2. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J et al (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355:885-895 (Pubitemid 44315981)
3. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C (1999) Stat3 as an oncogene. Cell 98:295-303 (Pubitemid 29380565)
4. Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH, Steiner H et al (2007) The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 26:2822-2832 (Pubitemid 46701444)
5. Chen WG, Daines MO, Khurana Hershey GK (2004) Turning off signal transducer and activator of transcription (STAT): The negative regulation of STAT signaling. J Allergy Clin Immunol 114:476-489 (Pubitemid 39194916)
6. Dixon DA (2004) Dysregulated post-transcriptional control of COX-2 gene expression in cancer. Curr Pharm Des 10:635-646 (Pubitemid 38292390)
7. Gong XF, Wang MW, Tashiro S, Onodera S, Ikejima T (2006) Involvement of JNK-initiated p53 accumulation and phosphorylation of p53 in pseudolaric acid B induced cell death. Exp Mol Med 38:428-434
8. Grivennikov S, Karin M (2008) Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 13:7-9 (Pubitemid 350309747)
9. Grivennikov SI, Karin M (2010) Dangerous liaisons: STAT3 and NFkappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21:11-19
10. Hou GQ, Zhang Q, Wang LL, Liu MY, Wang JR, Xue LX (2010) mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice. Cancer Lett 290:248-254
11. Jorissen RN, Walker F, Pouliot N, Garrett TPJ, Ward CW, Burgess AW (2003) Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res 284:31-53 (Pubitemid 36331965)
12. Kim HS, Cho IH, Kim JE, Shin YJ, Jeon JH, Kim Y et al (2008) Ethyl pyruvate has an anti-inflammatory effect by inhibiting ROSdependent STAT signaling in activated microglia. Free Radical Bio Med 45:950-963
13. Ko JKS, Leung WC, Ho WK, Chiu P (2007) Herbal diterpenoids induce growth arrest and apoptosis in colon cancer cells with increased expression of the nonsteroidal anti-inflammatory drugactivated gene. Eur J Pharmacol 559:1-13 (Pubitemid 46274648)
14. Kojima M, Morisaki T, Izuhara K, Uchiyama A, Matsunari Y, Katano M et al (2000) Lipopolysaccharide increases cyclo-oxygenase-2 expression in a colon carcinoma cell line through nuclear factorkB activation. Oncogene 19:1225-1231 (Pubitemid 30157553)
15. Kraus S, Arber N (2009) Inflammation and colorectal cancer. Curr Opin Pharmacol 9:405-410
16. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z et al (2009) Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15:283-293
17. Li T, Wong VKW, Yi XQ, Wong YF, Zhou H, Liu L (2009) Pseudolaric acid B suppresses T lymphocyte activation through inhibition of NF-kappaB signaling pathway and p38 phosphorylation. J Cell Biochem 108:87-95
18. Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia WY, Wei YK et al (2005) Nuclear interaction of p-EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 7:575-589 (Pubitemid 40799250)
19. Macarthur M, Hold GL, El-Omar EM (2004) Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 286:G515-G520 (Pubitemid 38374969)
20. Maier TJ, Schilling K, Schmidt R, Geisslinger G, Grösch S (2004) Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 67:1469-1478 (Pubitemid 38388209)
21. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436-444
22. Meng AG, Jiang LL (2009) Induction of G2/M arrest by pseudolaric acid B is mediated by activation of the ATM signaling pathway. Acta Pharmacol Sin 30:442-450
23. Naugler WE, Karin M (2008) The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 14:109-119
24. Ogunwobi OO, Beales ILP (2006) Glycine-extended gastrin stimulates proliferation and inhibits apoptosis in colon cancer cells via cyclo-oxygenase-independent pathways. Regul Pept 134:1-8
25. Pan DJ, Li ZL, Hu CQ, Chen K, Chang JJ, Lee KH (1990) The cytotoxic principles of Pseudolarix kaempferi: pseudolaric acid- A and-B and related derivatives. Planta Med 56:383-385 (Pubitemid 20339439)
26. Roessner A, Kuester D, Malfertheiner P, Schneider-Stock R (2008) Oxidative stress in ulcerative colitis-associated carcinogenesis. Pathol Res Pract 204:511-524
27. Seruga B, Zhang H, Bernstein LJ, Tannock IF (2008) Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 8:887-899
28. Shiff SJ, Shivaprasad P, Santini DL (2003) Cyclooxygenase inhibitors: drugs for cancer prevention. Curr Opin Pharmacol 3:352-361 (Pubitemid 36908938)
29. Simpson PB, Wafford KA (2006) New directions in kinetic high information content assays. Drug Discov Today 11:237-244
30. Tak PP, Firestein GS (2001) NF-jB: a key role in inflammatory diseases. J Clin Invest 107:7-11 (Pubitemid 32047405)
31. Tan WF, Li MH, Chen Y, Ding J (2004) Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect. Eur J Pharmacol 499:219-228 (Pubitemid 39233660)
32. Terzic0 J, Grivennikov S, Karin E, Karin M (2010) Inflammation and colon cancer. Gastroenterology 138:2101-2114
33. Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anti-cancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252-266 (Pubitemid 34196319)
34. Tong YG, Zhang XW, Geng MY, Yue JM, Xin XL, Tian F et al (2006) Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin. Mol Pharmacol 69:1226-1233
35. Wang D, DuBois RN (2008) Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett 267:197-203
36. Wong VK, Chiu P, Chung SS, Chow LM, Zhao YZ, Yang BB et al (2005) Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo. Clin Cancer Res 11:6002-6011 (Pubitemid 41170332)
37. Wu T (2006) Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev 32:28-44 (Pubitemid 43159775)
38. Yu ZY, Zhang WZ, Kone BC (2002) Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB. Biochem J 367:97-105 (Pubitemid 35176895)
39. Yu H, Kortylewski M, Pardoll D (2007a) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature Rev Immunol 7:41-51 (Pubitemid 46020826)
40. Yu JH, Cui Q, Jiang YY, Yang W, Tashiro SI, Onodera S et al (2007b) Pseudolaric acid B induces apoptosis, senescence, and mitotic arrest in human breast cancer MCF-7. Acta Pharmacol Sin 28:1975-1983 (Pubitemid 350198348)
41. Yu JH, Wang HJ, Li XR, Tashiro SI, Onodera S, Ikejima T (2008) Protein tyrosine kinase, JNK, and ERK involvement in pseudolaric acid B induced apoptosis of human breast cancer MCF-7 cells. Acta Pharmacol Sin 29:1069-1076